orafenib suppresses hepatitis B virus gene expression via inhibiting JNK pathway

发表时间：2015-11-12 浏览次数：1137次

引用：

Cho HK, Kim JR, Kim SY, Kyaw YY, Win AA, Cheong JH. Sorafenib suppresses hepatit

关键词：

作者：

Hyun Kook Cho1, Ju Ran Kim1, So Young Kim1, Yi Yi

作者单位：

1 Department of Molecular Biology, Pusan National

出版年份：

2015

期刊页数：

97-103

收录者：

其他外文数据库

摘要：

Hepatitis B virus (HBV) infection is a major cause of chronic liver diseases. Sorafenib is a multikinase inhibitor and an approved anti-liver cancer drug. Here we demonstrated the antiviral effect of sorafenib on HBV gene expression. Methods: To investigate the effect of sorafenib on HBV gene expression, a luciferase assay was performed with Χ1.3 Cp-luciferase HBV construct and reverse transcriptase polymerase chain reaction (PCR), real-time PCR, and Western blotting analyses were performed using HepG2 cells derived from hepatocellular carcinoma and Chang liver cells derived from a normal liver tissue. Results: Sorafenib suppressed HBV gene expression via inhibiting the JNK pathway. In this process, the farnesoid X receptor (FXR), a transcription factor that has been reported to increase HBV replication and gene expression, was under control of the JNK pathway. Notably, JNK activation increased FXR protein levels, not mRNA levels. Conclusion: Sorafenib suppressed HBV gene expression via inhibiting the JNK pathway, which regulates FXR activity.

阅读全文